N4 Pharma Plc

ONZ

GB00BYW8QM32

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:05 2024-04-26 am EDT			5-day change	1st Jan Change
0.775 ^GBX	-6.06%		-8.82%	-8.82%

Apr. 25	N4 Pharma strikes partnership deal for intracellular delivery	AN
Apr. 23	N4 Pharma loss widens but "great optimism" remains	AN

N4 Pharma shares rise on "encouraging" Nuvec research

February 15, 2024 at 07:08 am EST

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Current stock price: 0.83 pence, up 11%

12-month change: down 63%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about N4 Pharma Plc

N4 Pharma strikes partnership deal for intracellular delivery	Apr. 25	AN
N4 Pharma loss widens but "great optimism" remains	Apr. 23	AN
N4 Pharma Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
N4 Pharma sees potential in Nuvec delivery method for cancer treatment	Apr. 18	AN
N4 Pharma’s In Vivo Testing Shows Nuvec’s Potential as Oral Delivery System	Apr. 18	MT
N4 Pharma's In-vitro Study Shows Nuvec's Versatility in Inhibiting Cancer Cells	Feb. 15	MT
N4 Pharma shares rise on "encouraging" Nuvec research	Feb. 15	AN
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets	Feb. 15	AN
N4 Pharma plc Provides In-Vitro siRNA Update	Feb. 15	CI
N4 Pharma's Nuvec Granted Patent in India	Jan. 19	MT
N4 Pharma gets India patent for medical delivery system	Jan. 19	AN
N4 Pharma touts contract to test glaucoma treatment, ECP105	Jan. 16	AN
N4 Pharma Unit to Prepare Glaucoma Treatment Candidate for Pre-clinical Trials; Shares Plunge	Jan. 16	MT
N4 Pharma Shows Increased Transduction Efficacy for Silica Nanoparticle	Jan. 08	MT
N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8	Jan. 08	AN
N4 Pharma plc Provides A Further Successful Update on Its Ongoing Research Work into the Use of Nuvec to Enhance the Performance of Viral Vector	Jan. 08	CI
FTSE 100 outperforms European peers	Dec. 18	AN
N4 Pharma rises on successful results from Nuvec administration	Dec. 18	AN
N4 Pharma Plc Provides Positive Update on its Ongoing Oral Delivery Research Work	Dec. 18	CI
N4 Pharma hails "encouraging" siRNA research	Dec. 07	AN
N4 launches investor hub; Capricorn production falls	Dec. 01	AN
Transcript : N4 Pharma Plc, Nanogenics Ltd. - M&A Call	23-10-16
FTSE 100 Closes Thursday Slightly Up as Gilt Yields Weigh on Index	23-09-28	DJ
N4 Pharma shares fall as places shares to fund Nanogenics stake buy	23-09-28	AN
N4 Pharma Buys 71% Stake in Biotechnology Company Nanogenics; Stock Plummets	23-09-28	MT

Chart N4 Pharma Plc

Duration

Period

More charts

Company Profile

N4 Pharma Plc is a United Kingdom-based specialist pharmaceutical company. The Company is focused on developing a silica nanoparticle delivery system to improve the cellular delivery of cancer treatments and vaccines. The Company is engaged in the development and commercialization of medicines through its delivery system, Nuvec. Nuvec is a silica nanoparticle technology with a patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical Phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. The Companyâs wholly owned subsidiaries include N4 Pharma UK Limited.

Sector

Pharmaceuticals

Calendar

2024-09-17 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
N4 PHARMA PLC	-8.82%	2.59M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B